- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
New Hepatitis C Therapies ; volume:34 ; number:01 ; year:2014 ; pages:007-008
Seminars in liver disease ; 34, Heft 01 (2014), 007-008
- Beteiligte Personen und Organisationen
-
Pawlotsky, Jean-Michel
- DOI
-
10.1055/s-0034-1371178
- URN
-
urn:nbn:de:101:1-2019040811293451973274
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pawlotsky, Jean-Michel
Ähnliche Objekte (12)
Stem cell therapies for autoimmune hepatitis
Immune therapies against chronic hepatitis B
Emerging therapies for the treatment of hepatitis C
Comparing drug safety of hepatitis C therapies using post-market data
New therapies in multiple myeloma
Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B
New Avenues for Nanoparticle-Related Therapies
Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
Assessing patient preferences for treatment decisions for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infections
Diabetes mellitus: new challenges and innovative therapies
Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients
Stem cell therapies for autoimmune hepatitis
Immune therapies against chronic hepatitis B
Emerging therapies for the treatment of hepatitis C
Comparing drug safety of hepatitis C therapies using post-market data
New therapies in multiple myeloma
Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B
New Avenues for Nanoparticle-Related Therapies
Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
Assessing patient preferences for treatment decisions for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infections
Diabetes mellitus: new challenges and innovative therapies
Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients
Stem cell therapies for autoimmune hepatitis
Immune therapies against chronic hepatitis B
Emerging therapies for the treatment of hepatitis C
Comparing drug safety of hepatitis C therapies using post-market data
New therapies in multiple myeloma
Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B
New Avenues for Nanoparticle-Related Therapies
Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
Assessing patient preferences for treatment decisions for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infections
Diabetes mellitus: new challenges and innovative therapies